← Companies|Karuna (BMS)
Ka

Karuna (BMS)

Boston MAFounded 2009800 employees
Private CapbiotechAcquiredCNS
Platform: Muscarinic
Market Cap
N/A
All Drugs
3
Clinical Trials
4
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
KAR-3569KAR-3569NDA/BLA1Small MoleculeCDK2MALT1iMMAML
PolatinibKAR-1513Phase 11Cell TherapyPARPJAK1iPBCOvarian Ca
SotofutibatinibKAR-8988Phase 1/22DegraderKRASG12DCD3xCD20Myelofibrosis
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (3)
2025-04-02
KAR-3569 Ph3 Readout
MM
Past
2027-09-22
Sotofutibatinib Ph2 Data
Myelofibrosis
Ph2 Data
2028-02-16
Polatinib Interim
Psoriasis
Interim